Nabi Drops StaphVAX Following Failure Of Confirmatory Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm also halts development of S. aureus immune globulin Altastaph because it uses the same technology as the StaphVax S. aureus vaccine.
You may also be interested in...
Nabi Reports Positive Phase IIb Results For Anti-Smoking Vaccine NicVAX
Firm is in competition with Novartis/Cytos to get a smoking vaccine to market.
Nabi Reports Positive Phase IIb Results For Anti-Smoking Vaccine NicVAX
Firm is in competition with Novartis/Cytos to get a smoking vaccine to market.
Nabi’s StaphVAX Development Back On Track
The company is seeking a partner for the re-launch of its gram-positive bacteria vaccine program.